OTCBB ALERTS

[Mandroid]

Lifeline Biotechnologies, Inc. LBTN) today announced a common stock dividend which will be issued to its
shareholders of record as of April 14, 2006. The stock dividend will
total approximately 50 Million unrestricted shares of LBTN. Lifeline
Biotechnologies shareholders are expected to receive approximately one
and a half shares of LBTN for each ten shares already owned on the
record date.
"This stock dividend to shareholders is a reward for their
continued support as we focus on the increased marketing efforts of
our MastaScope(TM) and the development of our First Warning System(TM)
and OvaScope(TM). We are very pleased to be in a position to give back
to our loyal shareholders and show our appreciation," stated Jim
Holmes, CEO of Lifeline Biotechnologies, Inc.

About Lifeline Biotechnologies, Inc.

Lifeline Biotechnologies, Inc. is a company with innovative
medical technologies committed to the improvement of the quality of
life through exceptional health care systems. These technologies focus
on prevention, early detection, diagnosis and quick recovery of a
number of disease conditions. The company's technologies, designed to
assist in the early detection of cancers, deal with cutting edge
innovation to assist practicing physicians in the delivery of quality
medical care. The MastaScope(TM) is used to assist in the early
detection of cancer and other abnormalities of the breast. The
MastaScope(TM) has completed development and has entered the
marketplace in the US and internationally. The First Warning
System(TM) for assisting in the early detection of breast cancer and
the OvaScope(TM) for assisting in the early detection of ovarian
cancer are continuing to be developed by the company. More information
is available at the company's website: www.lbti.com.
Safe Harbor This release includes forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 27E of the Securities Act of 1934. Statements contained in
this release that are not historical facts may be deemed to be
forward-looking statements. Investors are cautioned that
forward-looking statements are inherently uncertain. Actual
performance and results may differ materially from that projected or
suggested herein due to certain risks and uncertainties including,
without limitation, ability to obtain financing and regulatory and
shareholder approval for anticipated actions.



KEYWORD: NORTH AMERICA NEVADA UNITED STATES
INDUSTRY KEYWORD: WOMEN HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES ONCOLOGY RESEARCH & SCIENCE CONSUMER DIVIDEND
SOURCE: Lifeline Biotechnologies, Inc.


CONTACT INFORMATION:
for Lifeline Biotechnologies, Inc.
Big Apple Consulting USA, Inc.
Rodney Marvel, 407-884-0444
1-866-THE-APPL(E)